Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Inclusion Criteria: * Histologically confirmed classical Hodgkin's lymphoma * No bone marrow biopsies or fine needle aspirates as the sole means of diagnosis * Core biopsies allowed if they contain adequate tissue for primary diagnosis * The following subtypes are allowed: * Nodular sclerosis * Lymphocyte rich * Mixed cellularity * Lymphocyte depletion * Classical Hodgkin's lymphoma, not otherwise specified * No nodular lymphocyte-predominant Hodgkin's lymphoma * Relapsed or refractory disease after at least 1 prior standard systemic cytotoxic chemotherapy regimen * Measurable disease by physical exam or imaging studies * Any tumor mass \> 1 cm is allowed * No non-measurable disease only, including the following: * Bone lesions * Ascites * Pleural or pericardial effusion * Lymphangitis cutis/pulmonis * Bone marrow * No curative option available with high-dose therapy and stem cell transplantation * Performance status - 0-2 * Absolute neutrophil count ≥ 750/mm\^3 * Platelet count ≥ 75,000/mm\^3 * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST ≤ 2.5 times ULN * Creatinine ≤ 2.5 mg/dL * No sensory or motor peripheral neuropathy ≥ grade 2 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for up to 3 months after study participation * See Disease Characteristics * Prior stem cell transplantation allowed * See Disease Characteristics * No concurrent chemotherapy * No concurrent dexamethasone or other steroidal antiemetics * Concurrent steroids for adrenal failure allowed * Concurrent hormonal therapy for non-disease related conditions (e.g., insulin for diabetes) allowed * Prior radiotherapy to a symptomatic lesion or one that may produce disability (e.g., unstable femur) is allowed provided other measurable disease is present * No concurrent palliative radiotherapy * Recovered from all prior treatment * No prior bortezomib or other proteosome inhibitors